TAK icon

Takeda Pharmaceutical

15.29 USD
+0.01
0.07%
At close Apr 30, 4:00 PM EDT
After hours
15.29
+0.00
0.00%
1 day
0.07%
5 days
1.87%
1 month
2.82%
3 months
11.61%
6 months
10.08%
Year to date
15.40%
1 year
16.90%
5 years
-14.77%
10 years
-11.41%
 

About: Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Employees: 49,281

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

4,520% more call options, than puts

Call options by funds: $22.9M | Put options by funds: $496K

7% more repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 94

5% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 42

0.26% less ownership

Funds ownership: 4.79% [Q3] → 4.53% (-0.26%) [Q4]

2% less funds holding

Funds holding: 298 [Q3] → 293 (-5) [Q4]

6% less capital invested

Capital invested by funds: $1.02B [Q3] → $954M (-$62.3M) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for TAK.

Financial journalist opinion

Based on 10 articles about TAK published over the past 30 days

Positive
Zacks Investment Research
14 hours ago
Are You Looking for a Top Momentum Pick? Why Takeda Pharmaceutical Co. (TAK) is a Great Choice
Does Takeda Pharmaceutical Co. (TAK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are You Looking for a Top Momentum Pick? Why Takeda Pharmaceutical Co. (TAK) is a Great Choice
Positive
Zacks Investment Research
16 hours ago
Best Value Stocks to Buy for April 30th
SKM, TAK and PHIN made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 30, 2025.
Best Value Stocks to Buy for April 30th
Positive
Zacks Investment Research
18 hours ago
Best Income Stocks to Buy for April 30th
SKM, TAK and SONY made it to the Zacks Rank #1 (Strong Buy) income stocks list on April 30, 2025.
Best Income Stocks to Buy for April 30th
Neutral
Business Wire
19 hours ago
Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda has awarded grants to seven nonprofits that share its commitment to creating better health for people and a brighter future for the world.
Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education
Positive
Zacks Investment Research
21 hours ago
New Strong Buy Stocks for April 30th
DB, SPOT, SONY, CIVB and TAK have been added to the Zacks Rank #1 (Strong Buy) List on April 30, 2025.
New Strong Buy Stocks for April 30th
Positive
Zacks Investment Research
1 week ago
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
Neutral
Zacks Investment Research
2 weeks ago
TAK vs. DSNKY: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
TAK vs. DSNKY: Which Stock Is the Better Value Option?
Neutral
Accesswire
3 weeks ago
BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3
LUND, SWEDEN / ACCESS Newswire / April 8, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that it has earned a 1 million USD milestone payment, following Takeda's (TSE:4502/NYSE:TAK) initiation of Phase 3 clinical trial of mezagitamab (TAK-079), identified from BioInvent's proprietary n-CoDeR® antibody library. The study is evaluating this potential best-in-class anti-CD83 monoclonal antibody for persistent or chronic primary immune thrombocytopenia (ITP).
BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3
Positive
Zacks Investment Research
3 weeks ago
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
Positive
Seeking Alpha
4 weeks ago
Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns
Takeda's AI-powered "returning to growth" program has improved profit margins, leading to upgraded FY2024 guidance and a JPY100 billion share buyback program. Takeda's Rusfertide and Protagonist's Icotrokinra show strong Phase III results, with potential regulatory approvals and launches by 2026, boosting revenue prospects. Protagonist's financial stability, with a cash runway until 2028, supports a "Strong Buy" rating for high-risk tolerant investors.
Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns
Charts implemented using Lightweight Charts™